GlassScriptPhysician profile
Maritza Balzarini
NPI 1114770849
$2,507.63
in general payments reported to CMS, 2019-2025
19 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $961 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $371.83 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.53 | 2024-2025 | Jardiance |
| Medtronic, INC. | $308.08 | 2025 | Aurora Ev-Icd Mri Surescan, Symplicity G3, Venaseal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $294.60 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $239.84 | 2024-2025 | |
| Boston Scientific Corporation | $136.90 | 2024-2025 | Watchman Flx, Eluvia |
| Abbvie INC. | $124.99 | 2024 | |
| Cvrx, INC. | $122.01 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $106.65 | 2024-2025 | Farxiga, Wainua |
| Abiomed | $98.33 | 2024 | Impella |
| Inspire Medical Systems, INC. | $86.09 | 2025 | Inspire |
| Amgen INC. | $58.91 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $52.48 | 2025 | |
| Scpharmaceuticals INC. | $26.62 | 2025 | |
| Jubilant Draximage, INC. | $25.43 | 2025 | Technetium Tc 99m Sestamibi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $25.01 | 2024 | |
| Novo Nordisk INC | $24.04 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $20.32 | 2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $15.97 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maritza Balzarini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.